Wells Fargo downgraded Becton Dickinson from Overweight to Equal Weight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2025 | $185.00 | Buy → Neutral | Citigroup |
| 5/2/2025 | $185.00 | Overweight → Neutral | Piper Sandler |
| 5/2/2025 | $192.00 | Buy → Neutral | Goldman |
| 5/2/2025 | Outperform → Mkt Perform | Raymond James | |
| 5/1/2025 | Overweight → Equal Weight | Wells Fargo | |
| 5/1/2025 | $190.00 | Buy → Neutral | BofA Securities |
| 5/1/2025 | Outperform → Mkt Perform | William Blair | |
| 10/1/2024 | $255.00 → $275.00 | Neutral → Buy | Citigroup |
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
SD - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
Revenue of $5.3 billion increased 4.5% as reported, 6.0% currency-neutral and 0.9% organicGAAP and adjusted diluted EPS of $1.07 and $3.35, respectivelyCompany updates full-year fiscal 2025 guidance and provides estimated tariff impactFRANKLIN LAKES, N.J., May 1, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025. "Amid a difficult operating environment impacting near-term organic revenue growth, our Q2 results reflect the strength of our business model and ability to exceed our earnings expectations through quality gross margin improvement," s
FRANKLIN LAKES, N.J., April 29, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, payable on June 30, 2025 to holders of record on June 9, 2025. The indicated annual dividend rate is $4.16 per share. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advanc
Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organicGAAP and adjusted diluted EPS of $1.04 and $3.43 grew 8.3% and 28.0%, respectivelyBD completes $750 million share repurchase to date in FY25Company increases FY25 adjusted diluted EPS guidance at the midpoint while absorbing translational currency1FRANKLIN LAKES, N.J., Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2025 first quarter which ended December 31, 2024. "We delivered strong operational performance in Q1, with